The history of the erectile dysfunction drug presents a intricate picture for investors. While the initial introduction generated substantial returns, the lapse of its intellectual property protection opened the avenue to off-brand versions, dramatically reducing revenue. This presents a particular dilemma for firms relying on comparable blockbuste

The story of Viagra, and its creator copyright, presents a challenging case study for investors. Initially a blockbuster drug, producing billions in income, its intellectual property lapse created a wave of lower-priced alternatives , significantly diminishing its dominance. While specific pharmaceutical companies may try to capitalize on similar c